Shah Pritesh
SEC CIK 1744884 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| NVCR | NovoCure Ltd | Chief Growth Off | 124.5K | — | $3.77M | 20 | 2021-07-06 | 2023-11-07 |
Most active insiders at NVCR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DOYLE WILLIAM F | Executive COB, Dir | — | $933.1K |
| 2 | Leonard Frank X | EVP, Pres, Novocure Oncology | — | $919.8K |
| 3 | Paravasthu Mukund | COO | — | $693.8K |
| 4 | Weinberg Uri | Chf Medical, Innovation Ofr | — | $232.2K |
| 5 | Brackmann Christoph | CFO | — | $85.3K |
| 6 | Stafford Kristin | Dir | — | $46.4K |
| 7 | Ocean Allyson J | Dir | — | $46.4K |
| 8 | Scannell Timothy J | Dir | — | $46.4K |
| 9 | VERNON W ANTHONY | Dir | — | $46.4K |
| 10 | Hung David | Dir | — | $46.4K |
Shah Pritesh made no open-market trades at NVCR in the last 12 months.
Transactions 20
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-08 | 2023-11-07 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | S - Sale | $12.65 | -382 | 124.5K | -0.3% | -$4,832 | |
| 2023-09-05 | 2023-09-01 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | S - Sale | $21.82 | -273 | 124.9K | -0.2% | -$5,957 | |
| 2023-07-06 | 2023-06-30 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | A - Grant | $35.28 | +367 | 125.2K | +0.3% | +$12.9K | |
| M | 2023-03-07 | 2023-03-03 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | S - Sale | $76.16 | -21.4K | 144.7K | -13% | -$1.63M |
| M | 2023-03-06 | 2023-03-03 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | A - Grant | $0.00 | +47.2K | 103.0K | +85% | $0 |
| 2023-03-06 | 2023-03-02 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | S - Sale | $75.28 | -937 | 99.0K | -0.9% | -$70.5K | |
| D | 2023-03-02 | 2023-02-28 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | A - Grant | $0.00 | +19.1K | 101.9K | +23% | $0 |
| D | 2023-03-02 | 2023-03-01 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Growth Off | S - Sale | $76.36 | -1,923 | 100.0K | -2% | -$146.8K |
| 2023-01-09 | 2023-01-05 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $108.00 | -387 | 82.8K | -0.5% | -$41.8K | |
| 2022-09-06 | 2022-09-02 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $79.04 | -269 | 83.2K | -0.3% | -$21.3K | |
| 2022-07-07 | 2022-07-05 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | A - Grant | $59.08 | +312 | 83.5K | +0.4% | +$18.4K | |
| D | 2022-03-11 | 2022-03-09 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale+OE | $71.19 | -3,669 | 83.2K | -4% | -$261.2K |
| D | 2022-03-11 | 2021-07-31 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | M - OptEx | $154.01 | +3,717 | 85.6K | +5% | +$572.5K |
| M | 2022-03-09 | 2022-03-07+ | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $69.73 | -7,775 | 84.4K | -8% | -$542.1K |
| D | 2022-03-07 | 2022-03-03 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | A - Grant | $0.00 | +21.7K | 95.2K | +30% | $0 |
| DM | 2022-03-07 | 2022-03-03+ | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $72.54 | -5,543 | 89.7K | -6% | -$402.1K |
| M | 2021-09-07 | 2021-09-02+ | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $138.57 | -657 | 73.7K | -0.9% | -$91.0K |
| 2021-08-06 | 2021-08-04 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $148.71 | -2,063 | 74.2K | -3% | -$306.8K | |
| 2021-08-04 | 2021-08-03 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | S - Sale | $149.43 | -1,654 | 76.2K | -2% | -$247.2K | |
| 2021-07-08 | 2021-07-06 | NVCR | NovoCure Ltd | Shah Pritesh | Chief Commercial Off | A - Grant | $137.12 | +154 | 77.9K | +0.2% | +$21.1K |
Purchase Sale Sale after option exercise All abbreviations